Vendor Intelligence Report: Platinum Cryo

Executive summary

Across 24 Finnrick lab tests, Platinum Cryo recorded 9 passes and 15 failures, an overall pass rate of 38%. The tested catalog is small and uneven, with no clean product signal. Retatrutide is the least weak option in the set but remains fail-majority; Ipamorelin is a split-record product; Melanotan II is the clearest avoid signal, with Semaglutide also weak. Ratings also contract under stricter Finnrick grading, so the default score does not mask a sturdier quality picture.

Platinum Cryo presents as an Akron, Ohio peptide vendor, but the public corporate trail is thin. The domain record and Wayback timeline point to an Oct. 2023 domain registration and early 2024 archive, while the company has claimed a longer 2022 history. Ohio, Delaware, and OpenCorporates checks did not identify a matching legal entity, and a legacy/sister domain appears on early certificate records tied to the same storefront.

The marketing footprint is more visible than the ownership. DNS records show CRM and affiliate-tracking infrastructure, and the promotion network runs through code-bearing fitness and peptide influencers. A restricted Reddit community tied to Nick Culp's affiliate channels is a particularly important review-context finding: it is not the same as an independent open forum, and the report stops short of calling Culp an owner.

The site's archived consumer-lifestyle framing later shifted into Research Use Only language, while affiliate posts continued to promote human-use outcomes. Platinum Cryo's public COA library gives more visibility than no documentation at all, but it leans on Chromate Labs, and the report traces a public correction history involving peptide misidentifications.

Inside the full report:

• Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 4 tested products
• RDAP, DNS, SPF, Cloudflare, and certificate-transparency analysis for platinumcryo.io and the sister-domain trail
• Corporate-registry search results across Ohio, Delaware, OpenCorporates, plus the Colorado spa disambiguation
• Wayback evidence comparing February/August 2024 consumer branding with the later RUO posture
• Affiliate and social-graph exhibits covering Nick Culp, the restricted subreddit, referral codes, and the SliceWP/GoHighLevel stack
• COA-library analysis and Chromate Labs correction-history context

Risk assessment

• Melanotan II product-quality risk — high: Finnrick records 6 Melanotan II tests with 2 pass / 4 fail and a 48.52% rating, the lowest of Platinum Cryo’s tested products.
• Semaglutide and Retatrutide product-quality risk — high: Both products show 6 tests with 2 pass / 4 fail; Retatrutide is the vendor’s strongest rating at 69.82%, but still fail-majority.
• Ipamorelin product-quality risk — medium: Ipamorelin shows 6 tests with 3 pass / 3 fail and a 62.78% rating; not fail-majority, but too inconsistent to treat as a clean product signal.
• Affiliate-promotion and controlled-review risk — high: Referral links/codes are documented across X, Instagram, Threads, Reddit, and coupon sites; disclosures are mostly no/unclear and the dedicated subreddit is Restricted under an affiliate-linked channel.
• Corporate-transparency risk — medium: No matching Ohio/Delaware/OpenCorporates entity or named officers were identified; the domain uses WhoisGuard privacy and Cloudflare.
• COA/testing-integrity risk — medium: Platinum Cryo’s visible COA library relies on Chromate Labs files, while a public GLP1 Forum thread documents Chromate corrections after early-2025 peptide misidentifications.
• Regulatory intended-use risk — medium: Current RUO language coexists with affiliate posts advertising human outcomes such as weight loss, muscle building, skin glow, and spot fat reduction.
• Brand-confusion and authenticity-verification risk — medium: The investigation found official platinumcryo.io, a linked legacy/sister platinumpeptides.io, and an unrelated platinumcryo.com spa, with no authoritative reseller/channel or anti-counterfeit list identified.
• Claims-verification risk — medium: The 2022 history, “10,000+ labs,” and “US-Based Manufacturing Only” claims were not corroborated by the supplied public records, facility evidence, or customer documentation.